Fundraising Fox

Immunomic Therapeutics

Rockville, US · Founded 2005 · Delaware corporation · 20 employees on LinkedIn · 2 known investors

Immunomic Therapeutics develops nucleic acid immunotherapy platforms, particularly self-amplifying RNA and plasmid DNA vaccines, for cancer treatment, allergies, and animal health applications. The company's UNITE® platform leverages lysosomal targeting technology to generate immune responses against CMV, HPV, and other tumor-associated antigens across multiple cancer types and allergic conditions.

BiotechMedical Devices

Founders & leadership

Immunomic Therapeutics was founded in 2005 by William G Hearl.

WG
William G HearlinChief Executive Officer and Director
DK
Dong-Gun KiminExecutive
CE
C. ERIC WINZERinChief Financial Officer and Director
BC
Bernard C RudnickChief Financial Officer
TH
Teri HeilandinVice President of Research and Development
BM
Bruce MacklerVice President and Director
WI
Winston I LoweChief Legal Officer and Secretary of the Board of Directors
LS
Lisa SalleyinChief Operating Officer

Board

YG
Yang Gon JinBoard director
SP
Steve ParkBoard director
KA
Ki-Hong AhnBoard director
RA
Robert AhlgrenBoard director

Investors · 2

Keiretsu ForumSan Francisco · $250K – $2M
Life Sciences Greenhouse InvestmentsHarrisburg · $250K – $500K

Reported raises · per SEC filings

Form D private placements

$100M disclosed across 7 rounds · 2011–2025

▶$6.5MraisedJun 2025 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Yang Gon JinDirector
  • Steve ParkDirector
  • Robert AhlgrenDirector
  • Dong-Gun KimExecutive Officer, Director
  • James WishartDirector
  • Ki-Hong AhnDirector
  • Matthew ChangDirector
Offering amount
$16M
Amount sold
$6.5M
First sale
May 2025
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$3MraisedApr 2024 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • James WishartDirector
  • Dong-Gun KimExecutive Officer, Director
  • C. ERIC WINZERExecutive Officer
  • Robert AhlgrenDirector
  • Steve ParkDirector
  • Ki-Hong AhnDirector
  • Matthew ChangDirector
  • Michael LackDirector
  • Ronald ThiboutotDirector
  • Yang Gon JinDirector
Offering amount
$20.9M
Amount sold
$3M
First sale
Jan 2024
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$77.7MraisedJan 2021 · 6 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • WILLIAM G. HEARLExecutive Officer, Director
  • C. ERIC WINZERExecutive Officer, Director
  • MICHAEL D. LACKDirector
  • JAMES W. WISHARTDirector
  • ALEX S KIMDirector
  • YANG-GON JINDirector
  • HYUK JOO JEEDirector
  • ARLO MCGINNDirector
  • RONALD P. THIBOUTOTDirector
Offering amount
$77.7M
Amount sold
$77.7M
Sales commissions
$3.1M
First sale
Feb 2020
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$314.5KraisedAug 2018 · 1 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • MICHAEL D. LACKDirector
  • WILLIAM G. HEARLExecutive Officer, Director
  • WILLIAM BARRY MCDONALDDirector
  • C. ERIC WINZERExecutive Officer, Director
  • JAMES W. WISHARTDirector
  • RONALD P. THIBOUTOTDirector
Offering amount
$314.5K
Amount sold
$314.5K
First sale
Jul 2018
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$4.6MraisedMar 2017 · 47 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • WILLIAM G. HEARLExecutive Officer, Director
  • JAMES W. WISHARTDirector
  • RONALD P. THIBOUTOTDirector
  • WILLIAM BARRY MCDONALDDirector
  • C. ERIC WINZERExecutive Officer, Director
  • MICHAEL D. LACKDirector
Offering amount
$10M
Amount sold
$4.6M
Minimum investment
$25K
First sale
Feb 2017
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$6.8MraisedOct 2014 · 56 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William Barry McDonaldDirector
  • Teri Jones HeilandExecutive Officer
  • Bruce F. MacklerExecutive Officer, Director
  • Ronald ThiboutotDirector
  • James WishartExecutive Officer, Director
  • William G HearlExecutive Officer, Director, Promoter
  • Michael D. LackDirector
  • Bernard C. RudnickExecutive Officer, Director
Offering amount
$8.8M
Amount sold
$6.8M
Minimum investment
$10K
Sales commissions
$276K
Proceeds to insiders
$500K
Placement agents
Newport Coast Securities Inc.
First sale
Dec 2013
Incorporated
Corporation, Delaware
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$1.1MraisedMar 2012 · 7 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • William G HearlExecutive Officer, Director, Promoter
  • Bernard C RudnickExecutive Officer
  • William Barry McDonaldDirector
  • Teri HeilandExecutive Officer
  • Bruce MacklerExecutive Officer, Director
  • Ronald ThiboutotDirector
  • Winston I LoweExecutive Officer
  • James WishartDirector
  • Lisa SalleyExecutive Officer
Offering amount
$2M
Amount sold
$1.1M
Minimum investment
$50K
First sale
Aug 2011
Incorporated
Corporation, Delaware
Federal exemptions
06
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Competitors · 2

by search overlap
Immunome50 shared keywordsImmunome is a clinical-stage oncology company developing targeted cancer therapies, including antibody-drug conjugates (ADCs) and small molecules, to address unmet medical needs in cancers such as lymphoma and bladder cancer. It also acquires targeted oncology assets and advances them through manufacturing and clinical development.
IQVIA46 shared keywordsIQVIA is a healthcare data and technology company that supports life sciences organizations in research, clinical development, and commercialization of medicines and medical solutions.

Companies competing with Immunomic Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.

Non-dilutive funding · 2 SBIR/STTR awards

Federal grants — no equity taken
AgencyPhaseYearAmount
National Institutes of Health (NIH)National Institutes of HealthPhase I2015$308K
National Institutes of Health (NIH)National Institutes of HealthPhase I2014$334K

Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.

In the news

HLB helps insert more funding into Immunomic - Global Venturingglobalventuring.com · Apr 2020Articles - Immunomic Therapeuticsimmunomix.com · Aug 2017Immunomic Therapeutics Closes $3 Million Debt Pre-Series B Round - BioSpacebiospace.com · Jul 2013Immunomic Therapeutics 4/25/2014 Capital Raise - Gaebler.com Venture Capital Databasegaebler.com

Frequently asked questions

What does Immunomic Therapeutics do?
Immunomic Therapeutics develops nucleic acid immunotherapy platforms, particularly self-amplifying RNA and plasmid DNA vaccines, for cancer treatment, allergies, and animal health applications. The company's UNITE® platform leverages lysosomal targeting technology to generate immune responses against CMV, HPV, and other tumor-associated antigens across multiple cancer types and allergic conditions.
Who founded Immunomic Therapeutics?
Immunomic Therapeutics was founded by William G Hearl in 2005.
Who are Immunomic Therapeutics's investors?
Immunomic Therapeutics's investors include Keiretsu Forum, Life Sciences Greenhouse Investments.
How much funding has Immunomic Therapeutics raised?
Immunomic Therapeutics has disclosed $100M raised across 7 rounds.
Where is Immunomic Therapeutics headquartered?
Immunomic Therapeutics is headquartered in Rockville, US.